Published in Int J Nanomedicine on January 01, 2007
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine (2012) 1.94
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Dilemmas in the reliable estimation of the in-vitro cell viability in magnetic nanoparticle engineering: which tests and what protocols? Nanoscale Res Lett (2012) 0.97
Antitumoral activity of L-ascorbic acid-poly- D,L-(lactide-co-glycolide) nanoparticles containing violacein. Int J Nanomedicine (2010) 0.94
Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology (2013) 0.93
Free Rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy. J Nanobiotechnology (2011) 0.87
Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy. Int J Nanomedicine (2014) 0.86
Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo. PLoS One (2015) 0.86
Novel opportunities and challenges offered by nanobiomaterials in tissue engineering. Int J Nanomedicine (2008) 0.82
Carbon-covered magnetic nanomaterials and their application for the thermolysis of cancer cells. Int J Nanomedicine (2010) 0.80
Magnetic Properties of Polyvinyl Alcohol and Doxorubicine Loaded Iron Oxide Nanoparticles for Anticancer Drug Delivery Applications. PLoS One (2016) 0.78
Biogenic Fabrication of Iron/Iron Oxide Nanoparticles and Their Application. Nanoscale Res Lett (2016) 0.75
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials (2002) 3.12
Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem (2006) 2.87
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Clinical applications of magnetic drug targeting. J Surg Res (2001) 2.25
Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods (1982) 2.16
Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir (2005) 2.14
HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm (2000) 2.05
A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc (2004) 1.73
Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci (1995) 1.58
Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target (2003) 1.58
Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci Mater Med (2004) 1.36
Magnetically modulated therapeutic systems. Int J Pharm (2004) 1.30
Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res (1985) 1.21
Drug resistance reversal--are we getting closer? Eur J Cancer (2003) 1.18
Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today (2000) 1.17
Magnetoliposomes. Formation and structural characterization. Eur Biophys J (1988) 1.14
Preparation of immobilized proteins covalently coupled through silane coupling agents to inorganic supports. Appl Biochem Biotechnol (1993) 1.12
Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy. Analyst (2005) 1.12
Magnetic microspheres: synthesis of a novel parenteral drug carrier. J Pharm Sci (1979) 1.10
In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Res (1980) 1.02
Physical and Chemical Properties of Magnetite and Magnetite-Polymer Nanoparticles and Their Colloidal Dispersions. J Colloid Interface Sci (1999) 1.01
Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs (1998) 0.96
Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol (1983) 0.96
Synthesis and Characterization of Spherical Magnetite/Biodegradable Polymer Composite Particles. J Colloid Interface Sci (2001) 0.92
Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev (2001) 0.91
Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release (2001) 0.83
Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int J Pharm (2005) 0.80
Targeting cancer therapy. Br J Cancer (1999) 0.78
New magnetic drug carrier. J Pharm Pharmacol (1983) 0.77
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol (2005) 2.50
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56
Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy. Analyst (2005) 1.12
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol (2010) 1.04
Poly(ethylene glycol)-stabilized silver nanoparticles for bioanalytical applications of SERS spectroscopy. Analyst (2009) 0.95
Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos (2007) 0.90
Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med (2013) 0.89
Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. Eur J Pharm Biopharm (2007) 0.86
Conformational modifications of alpha gliadin and globulin proteins upon complex coacervates formation with gum Arabic as studied by Raman microspectroscopy. Biomacromolecules (2006) 0.86
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer (2011) 0.85
Intracellular applications of analytical SERS spectroscopy and multispectral imaging. Chem Soc Rev (2008) 0.85
Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells. Br J Haematol (2002) 0.82
SERS spectroscopic approach to study doxorubicin complexes with Fe(2+) ions and drug release from SPION-based nanocarriers. Analyst (2013) 0.78
Colloidal stability and thermo-responsive properties of iron oxide nanoparticles coated with polymers: advantages of Pluronic® F68-PEG mixture. Nanotechnology (2013) 0.78
Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. Int J Cancer (2007) 0.78
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. J Neurooncol (2009) 0.77
Analysis of doxorubicin distribution in MCF-7 cells treated with drug-loaded nanoparticles by combination of two fluorescence-based techniques, confocal spectral imaging and capillary electrophoresis. Anal Bioanal Chem (2015) 0.77
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. BJU Int (2015) 0.76
On the interaction of doxorubicin with oleate ions: fluorescence spectroscopy and liquid-liquid extraction study. Chem Pharm Bull (Tokyo) (2007) 0.75
Computer-assisted management of unconsumed drugs as a cost-containment strategy in oncology. Int J Clin Pharm (2014) 0.75
Patterned surfaces in the drying of films composed of water, polymer, and alcohol. Phys Rev E Stat Nonlin Soft Matter Phys (2012) 0.75
Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN). Int J Pharm (2013) 0.75
[Standards, Options and Recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)]. Bull Cancer (2003) 0.75
Ultra-filtration of human serum for improved quantitative analysis of low molecular weight biomarkers using ATR-IR spectroscopy. Analyst (2017) 0.75
Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study. Value Health (2008) 0.75